The G2019S leucine-rich repeat kinase 2 (LRRK2) mutation is the most common cause of genetic Parkinson's disease (PD). However, the molecular mechanism underlying LRRK2 G2019S-induced cellular pathology is poorly understood. Here, we demonstrated that LRRK2 G2019S bound to and phosphorylated Bcl-2, a mitochondrial anti-apoptotic protein, at Threonine 56. Either stable expression of Bcl-2 or transient expression of a Bcl-2 phosphor mutant (Bcl-2 T56A ) abolished LRRK2 G2019S-induced mitochondrial depolarization and autophagy. Together, our findings reveal a previously unidentified target of LRRK2 G2019S, showing that Bcl-2 serves as a point of crosstalk between LRRK2 G2019S-mediated mitochondrial disorder and dysregulation of autophagy.
Introduction
Parkinson's disease (PD) is one of the most common neurodegenerative disorders characterized by progressive and substantial loss of dopaminergic neurons in the substantia nigra [1, 2] . Various genetic mutations have been detected in PD; G2019S mutation of the Leucine Rich Repeat Kinase 2 (LRRK2) gene is the most common prevalent mutation in either genetic or sporadic PD [3] [4] [5] [6] [7] . LRRK2 is a large multidomain protein with a conserved serine-threonine kinase mitogenactivated protein kinase kinase kinase (MAPKKK) domain, a Roc GTPase domain and potential protein-protein interaction regions (leucine-rich repeat and WD40 domains) [8] [9] [10] . The G2019S mutant is associated with LRRK2 auto-phosphorylation, increased kinase activity and neurotoxicity [11] . Several recent lines of evidence have shown that the LRRK2 G2019S mutant causes mitochondrial dysfunction and aberrant autophagy in fibroblasts from PD patients with the mutation [12] [13] [14] [15] [16] , in dopaminergic neurons derived from induced pluripotent stem cells of PD patients [17] , and in transgenic mice in which a human LRRK2 G2019S mutant was expressed [18] . However, the signal that regulates LRRK2 G2019S-induced mitochondrial dysregulation and abnormal autophagy in the context of PD is poorly understood.
Bcl-2, a well-known mitochondrial anti-apoptotic factor, maintains the mitochondrial membrane potential (MMP) and mitochondrial integrity [19] [20] [21] [22] [23] . Direct binding of Bcl-2 to Beclin-1 inhibits the formation of Beclin-1/Vps34 complex and subsequent autophagosome formation [24, 25] . Thus, Bcl-2 has also been considered as a physiological inhibitor of Beclin-1-dependent autophagy [24, 25] . Therefore, Bcl-2 functions both as a pro-survival and anti-autophagic regulator.
In the present study, we showed that LRRK2 G2019S bound to and phosphorylated Bcl-2 at Thr56, which resulted in a loss of the MMP and led to p62/SQSTM1 association with the mitochondria, indicating that Bcl-2 phosphorylation initiates excessive mitophagy. Thus, LRRK2 G2019S-induced Bcl-2 Thr56 phosphorylation might represent an initiating point in the disruption of mitochondrial quality control, contributing to cellular damage in PD relevant to the G2019S mutation.
of protease inhibitor and cocktail of phosphatase inhibitor were purchased from Sigma-Aldrich (St. Louis, MO, USA). LRRK2 antibody was from Epitomics (Burlingame, CA, USA). Human recombinant LRRK2 and its mutant G2019S and D1994A, Tetramethylrhodamine (TMRM), FITC-labeled goat anti-rabbit Abs, Hoechst 33342, and Lipofectamine® 2000 Transfection Reagent were purchased from Invitrogen (Carlsbad, CA, USA). Lyso-ID Red dye was purchased from Enzo Life Sciences (Farmingdale, NY, USA) and a Cathepsin enzyme assay kit was from Biovision (Milpitas, CA, USA).
The LRRK2 (pDEST53-LRRK2-WT, plasmid 25044 [26] ) and its mutant (pDEST53-LRRK2-G2019S, plasmid 25045 [26] ; pDEST53-LRRK2-3XKD, plasmid 25049 [26] ) expression vectors, pGFP-Bcl2 (plasmid 17999 [27] ) and pGFP-Bcl2-Maob (plasmid 18001 [27] ) were purchased from Addgene (Cambridge, MA, USA). The T56A and T56D Bcl-2 full-length site-directed mutants were constructed by a mutagenesis reaction using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) and the pGFP-Bcl2 vector as template.
Cell culture
Human cervix carcinoma cells HeLa were maintained in Dulbecco's Modified Eagle Medium supplemented with 10% (v/v) heat-inactivated fetal calf serum and 1% (v/v) penicillin/streptomycin. LRRK2 G2019S patient fibroblasts (PD1: ND29802 from 52-year-old male PD patient; PD2: ND33879 from 66 year old female PD patient) were purchased from Coriell Institute. Normal adult fibroblast (HDFa) was from Invitrogen. The fibroblasts were maintained in Minimum Essential Medium supplemented with 15% (v/v) heat-inactivated fetal calf serum and 1% (v/v) penicillin/streptomycin.
Primary neurons from E18 rat midbrain tissue (BrainBits, Springfield, IL, USA) were seeded at about 50,000 cells on cover slides coated with poly-D-lysine/laminin in neurobasal medium supplemented with 2% B27 and 0.5 mM glutamate. At 7 DIV, cells were transfected with control vector GFP, LRRK2 G2019S, Bcl-2 T56A or Bcl-2 T56D using Lipofectamine™ 2000 Transfection Reagent combined with formulated BrainBits transfection media for primary neurons (BrainBits, USA). All cultured cells were maintained at 37°C in 5% CO 2 -95% air.
Isolation of mitochondrial-enriched fraction and lysate preparation
The mitochondria were isolated as described previously [28] . Briefly, cells were washed with cold phosphate-buffered saline (PBS) and incubated on ice in lysis buffer (250 mM sucrose, 20 mM HEPES-NaOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, protease inhibitor cocktail, phosphatase inhibitor cocktail) for 30 min. Cells were scraped and then disrupted 10 times by repeated aspiration through a 25 gauge needle, followed by a 30 gauge needle. The homogenates were spun at 800 g for 10 min at 4°C and the resulting supernatants were spun at 10,000 g for 20 min at 4°C. The pellets were washed with lysis buffer and spun at 10,000 g again for 20 min at 4°C. The final pellets were suspended in lysis buffer containing 1% Triton X-100 and were noted as mitochondrial-rich lysate fractions. The mitochondrial membrane protein VDAC was used as marker and loading control.
Immunocytochemistry
Cells were stained with antibodies against Tom20 (1:500) as described previously [28] . To measure the membrane potential of mitochondria in cultures, cells were incubated with 0.25 μM TMRM for 20 min at 37°C. To determine lysosomal activity, cells were incubated with Lyso-ID Red dye for 30 min at 37°C. The staining was imaged by a microscope, and quantification was carried out using NIH ImageJ software.
Citrate synthase activity assay
The cells were harvested, and 50 μg of lysate was added to each well of 96-well plate containing 160 μL of assay buffer (60 mM Tris-HCl, pH7.5, 200 μM Acetyl CoA, and 250 μM DTNB). The lysate was incubated for 5 min and then 20 μL of 2 mM oxaloacetate was added to each well. OD was measured at 412 nm for 30 min using a spectrometry plate reader. The rate of citrate synthase activity was quantified relative to control cells.
Measurement of autophagic flux
A difference in LC3 II levels in the presence and absence of Bafilomycin A1 (BFA) represents autophagic flux [29, 30] ; BFA prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes. To assess the autophagic flux, Hela cells were transfected with LRRK2 WT and G2019S mutant and treated with or without BFA (20 nM) for 2 h before cell harvest. Twenty-four hours after transfection, total lysates were harvested and western blots were performed. In patient fibroblasts, cells were pretreated with or without BFA (20 nM) for 2 h followed by western blot of total lysates. LC3 II band intensities were normalized to β-actin. Autophagy flux was then evaluated by the difference in normalized LC3 II band intensities with and without BFA treatment.
In vitro phosphorylation
Recombined human Bcl-2 (GST-tagged protein, 100 ng) was incubated with 50 ng of recombined human LRRK2 (GST-tagged protein consisting of amino acid residues 970-2527; either wild type, G2019S mutant, or D1994A mutant) in 25 μL of reaction mixture (40 mM TrisHCl, pH7.5, 2 mM dithiothreitol, 10 mM MgCl 2 , and 100 μM ATP). After incubation at 30°C for 30 min, the reaction was stopped by boiling in the sample-loading buffer for SDS-PAGE. The phosphorylation of Bcl-2 was detected by anti-serine-and/or anti-threonine-phosphorylation antibody.
Mass spectrometry analysis of phosphorylation site
Mass spectrometry analysis was performed in the Lerner Research Institute Proteomics Laboratory, Cleveland Clinic. Briefly, recombined human Bcl-2 (GST-tagged protein, 500 ng) was incubated with 500 ng of recombined human LRRK2 G2019S in 50 μL of reaction mixture (40 mM Tris-HCl, pH7.5, 2 mM dithiothreitol, 10 mM MgCl 2 , and 100 μM ATP). The reaction mixture was subjected to SDS-PAGE followed by Commassie blue staining. For the protein digestion, the bands of Bcl-2 were cut to minimize excess polyacrylamide, divided into a number of smaller pieces. The gel pieces washed with water and dehydrated in acetonitrile. The bands were then reduced with DTT and alkylated with iodoacetamide prior to the in-gel digestion. All bands were digested in-gel using trypsin, by adding 5 μL 10 ng/μL trypsin in 50 mM ammonium bicarbonate and incubating overnight digestion at room temperature to achieve complete digestion. The peptides that were formed were extracted from the polyacrylamide in two aliquots of 30 μL 50% acetonitrile with 5% formic acid. These extracts were combined and evaporated to b10 μL in Speedvac and then resuspended in 1% acetic acid to make up a final volume of~30 μL for LC-MS analysis.
The LC-MS system was a Finnigan LTQ-Obitrap Elite hybrid mass spectrometer system. The HPLC column was a Dionex 15 cm × 75 μm id Acclaim Pepmap C18, 2 μm, 100 Å reversed phase capillary chromatography column. Five μL volumes of the extract were injected and the peptides eluted from the column by an acetonitrile/0.1% formic acid gradient at a flow rate of 0.25 μL/min were introduced into the source of the mass spectrometer on-line. The microelectrospray ion source is operated at 2.5 kV. The digest was analyzed using the data dependent multitask capability of the instrument acquiring full scan mass spectra to determine peptide molecular weights and product ion spectra to determine amino acid sequence in successive instrument scans. This mode of analysis produces approximately 15,000 collisionally induced dissociation (CID) spectra of ions ranging in abundance over several orders of magnitude. Please note that not all CID spectra are derived from peptides.
The data were analyzed by using all CID spectra collected in the experiment to search the rodent reference sequence database using Mascot. All matching spectra were verified by manual interpretation. The interpretation process was aided by additional searches using the programs Sequest and Blast as needed.
Generation of stable cell line
Cells constitutively expressing GFP or GFP-Bcl-2 or GFP-Mito-Bcl-2 were obtained by transfection of HeLa cells with the pGFP or pGFPBcl-2 or pGFP-Bcl-2-Maob vectors, respectively, and selection with G418 (1 mg/mL).
Western blot analysis
Protein concentrations were determined by Bradford assay. Proteins (30 μg) were resuspended in Laemmli buffer, loaded on SDS-PAGE and transferred onto nitrocellulose membranes. Membranes were probed with the indicated antibody, followed by visualization by ECL.
Results

Concomitant occurrence of mitochondrial depolarization and mitochondrial mass loss in cells expressing LRRK2 G2019S
Primary fibroblasts from PD patients carrying the disease-associated mutations have been used as a cell culture model to observe mitochondrial phenotypes associated with PD [12, 13, 15] . In two lines of PD patient dermal fibroblasts carrying the LRRK2 G2019S mutation, we observed a dramatic loss of the mitochondrial membrane potential (MMP) when compared with that in normal fibroblasts (Fig. 1A) , which is consistent with previous studies [12, 31] . Moreover, by either staining cells with Tom20, a mitochondrial outer-membrane protein, or measuring citrate synthase activity, which reflects mitochondrial mass [32, 33] , we found a significant loss in mitochondrial mass in these PD patient fibroblasts, as evidenced by a decrease in the fluorescent density of Tom20 and a lower activity of citrate synthase (Fig. 1B and C) . These aberrant mitochondrial events were accompanied by an increase in autophagic flux (Fig. 1D) , which denotes the dynamic process of autophagy and is a more reliable indicator of autophagic activity [34] . Thus, an endogenous LRRK2 G2019S mutation might accelerate the process of autophagy. Given that depolarized mitochondria are selected for elimination via mitophagy [35, 36] , we speculated that the loss of mitochondrial mass in PD patient fibroblasts with the G2019S mutation is due to excessive mitophagy.
In parallel, we determined mitochondrial mass loss in HeLa cells in which either LRRK2 WT or the G2019S mutant was expressed. Consistent with the findings in PD patient fibroblasts (Fig. 1C) , the activity of citrate synthase was significantly decreased in both LRRK2 WT-and G2019S-expressing HeLa cells, which was corrected by treatment with Bafilomycin A1 [BFA, inhibits autophagy either by blocking autophagosome-lysosome fusion, or by blocking lysosomal degradation] (Fig. 1E) . Further, the fluorescent density of Tom20 was reduced in LRRK2 G2019S mutant-expressing HeLa cells, which was corrected by treatment with either BFA or NH 4 Cl (ammonium chloride, an inhibitor to inhibit lysosome activity) (Fig. 1F) . Together, the above data showed that either endogenous or exogenous expression of the LRRK2 G2019S mutation caused mitochondrial mass loss. Because of higher transfection efficiency, in the following study, we mainly used HeLa cells expressed with LRRK2 WT or G2019S mutants to determine potential molecular mechanism by which LRRK2 G2019S induces loss of mitochondrial mass.
P62/SQSTM1 is implicated in LRRK2 G2019S-induced excessive mitophagy
SQSTM1/p62 is a bridging protein between the ubiquitinated proteins/structures and the autophagosome component LC3 II [50] . Recruitment of STSTM1/p62 to the mitochondrial clusters has been considered to be an essential step for mitophagy [37] . Next, we determined whether p62 is involved in the mitophagic process induced by LRRK2 G2019S. Western blot of subcellular fractionations revealed that p62 translocated to the mitochondria in response to expression of LRRK2 WT and that this translocation was much enhanced in cells with the G2019S mutant ( Fig. 2A) . Next, we reduced the protein level of p62 by RNA interference (siRNA) and determined the mitochondrial mass and lysosomal activity. Down-regulation of p62 level corrected LRRK2 G2019S-induced mitochondrial mass loss (Fig. 2B) and suppressed G2019S-induced lysosome hyperactivity as demonstrated by a decrease in lyso-ID fluorescent density and a lower enzyme activity of lysosomal Cathepsin B (Fig. 2C and D) . Collectively, the above data indicate that the LRRK2 G2019S mutant causes excessive mitophagy likely via p62-mediated mitochondrial degradation. 
Bcl-2 is required for LRRK2 G2019S-induced excessive mitophagy
In this study, we found that the MMP was decreased in LRRK2 G2019S PD patient fibroblasts (Fig. 1A) . Bcl-2 plays a critical role in maintaining the MMP. The protein level of Bcl-2 was dramatically decreased in two lines of PD patient fibroblasts carrying the LRRK2 G2019S mutant (Fig. 3A) and in HeLa cells expressing with either LRRK2 WT or the G2019S mutant (Fig. 3B ). However, the protein level of Bcl-2 was not significantly altered in cells expressing the LRRK2 3XKD mutant (LRRK2 kinase-dead mutant), suggesting that the decrease in Bcl-2 protein level might be due to LRRK2 kinase activity. Given that Bcl-2 has the dual function of inhibition of autophagy and maintenance of the MMP [21, 22, 24] , we next asked whether Bcl-2 is involved in LRRK2 G2019S-induced excessive mitophagy.
To test this hypothesis, we generated stable HeLa cell lines expressing GFP, GFP-Bcl-2, or specific mitochondrial targeting GFP-Bcl-2 (GFP-M-Bcl-2). We found that LRRK2 G2019S-induced loss of the MMP was recovered in both GFP-Bcl-2 and GFP-M-Bcl-2 stable cells (Fig. 3C-lower panel) . Moreover, the G2019S-induced p62 translocation to the mitochondria was greatly reduced in both GFP-Bcl-2 and GFP-M-Bcl-2 stable cells, when compared with that in control GFP stable cells with the G2019S (Fig. 3D) . Further, increased autophagic flux and decreased mitochondrial mass induced by the G2019S mutant were corrected in both GFP-Bcl-2 and GFP-M-Bcl-2 stable cells ( Fig. 3E and F) . Taken together, these data demonstrated that Bcl-2 is an important element in LRRK2 G2019S-caused excessive mitophagy. However, the mechanism of LRRK G2019S-induced downregulation of Bcl-2 remains to be determined.
LRRK2 G2019S binds to and phosphorylates Bcl-2 at Threonine 56
The function of Bcl-2 is regulated by post-translational modification, such as phosphorylation [38] . LRRK2 is a serine-threonine kinase and its mutant G2019S augments its kinase activities [10] . Given that Bcl-2 alteration is dependent on LRRK2 kinase activity (Fig. 3B) , we next examined the possibility that Bcl-2 could be phosphorylated by LRRK2. Recombinant human Bcl-2 (GST-tagged protein) was subjected to an in vitro kinase assay by incubating with recombinant human LRRK2 (GST-tagged wide-type, G2019S mutant, and D1994A mutant (kinase dead) protein consisting of all the functional domains [amino acid residues 970-2527]). In addition to auto-phosphorylation of both LRRK2 WT and the G2019S mutant, we found that the G2019S mutant predominantly phosphorylated Bcl-2 protein at serine/threonine residues whereas the D1994 showed an inability to phosphorylate it (Fig. 4A) . Mass spectrometry analysis further revealed one conserved site, Thr56, which was phosphorylated by LRRK2 G2019S (Fig. 4B) . Using a specific phosphor antibody that recognizes Thr56 of Bcl-2, we confirmed that Bcl-2 was phosphorylated at this site by LRRK2 G2019S (Fig. 4C) . There was no significant Thr56 phosphorylation of Bcl-2 observed in cells expressing with either LRRK2 WT or 3XKD (Fig. 4C) . The Thr56 phosphorylation of Bcl-2 was also greatly increased in vitro when recombinant protein Bcl-2 was incubated with LRRK2 G2019S recombinant protein (Fig. 4D) . Finally, increased Thr56 phosphorylation of Bcl-2 was observed in the two LRRK2 G2019S PD patient fibroblast lines (Fig. 4E) . Thus, we concluded that Bcl-2 is a target of LRRK2 G2019S for phosphorylation.
Thr56 phosphorylation of Bcl-2 promotes excessive mitophagy
To determine the functional importance of Bcl-2 Thr56 phosphorylation in mitochondrial damage, we generated a Thr56 to alanine (Ala) mutant (Bcl2 T56A , non-phosphorylated) and to aspartic acid (Asp) mutant (Bcl-2 T56D , phosphomimetic) of Bcl-2. In HeLa cells coexpressing with either Bcl-2 WT or Bcl-2 T56A , the G2019S-induced loss of MMP was corrected (Fig. 5A) . However, phosphomimetic Bcl-2 (Bcl-2 T56D ) did not prevent the LRRK2 G2019S-induced MMP reduction (Fig. 5A ). These data suggest that Bcl-2 Thr56 phosphorylation is required for G2019S-induced mitochondrial depolarization. Further, in cells co-overexpressing LRRK2 G2019S with Bcl-2 WT or Bcl-2 T56A , a reduction of G2019S-induced conversion of LC3 from form I to form II, a marker of autophagy [39] , was observed (Fig. 5B) . Moreover, lysosome hyperactivity was completely abolished by expression of either Bcl-2 WT or Bcl-2 T56A in LRRK2
G2019S-expressing cells (Fig. 5C) . Concomitantly, the decrease in mitochondrial mass caused by the G2019S mutant was rescued by either Bcl-2 WT or Bcl-2 T56A expression (Fig. 5D) . Collectively, our findings showed that Thr56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and mitochondrial mass loss.
Thr56 phosphorylation of Bcl-2 caused neurite shortening in rat primary dopaminergic neurons expressing LRRK2 G2019S
Mouse cortical neurons expressing LRRK2 G2019S mutation displayed autophagic degradation of mitochondria and dendrite shortening [40] . LRRK2 G2019S expression in human neuroblastoma SH-SY5Y cells led to decrease in neurite length in association with increases in autophagic vacuoles [41] . These lines of evidence suggest an implication of aberrant mitophagy in neurodegeneration. Next, we examined the impact of Bcl-2 Thr56 phosphorylation on mitophagy in dopaminergic (DA) neurons expressing LRRK2 G20 19S. Primary rat midbrain DA neurons were co-expressed with LRRK2 G2019S with either Bcl-2 T56A or Bcl-2 T56D . Consistent with our findings above, we observed a great reduction of mitochondrial mass in LRRK2 G2019S-expressing DA neurons; however, coexpression of Bcl-2 T56A corrected this aberrant event (Fig. 6A) . Further, we stained neurons with anti-tyrosine hydroxylase (TH) antibody (a marker of DA neuron) to determine the neurite length of DA neurons. LRRK2 G2019S-expressing DA neurons exhibited shorter and fewer neurites, which is consistent with previous reports [41] . By contrast, co-expression of Bcl-2 T56A significantly improved neuronal morphology; the neurite length of DA neurons was increased from 28 to 86% relative to that in control vector-expressing neurons (Fig. 6B) . Taken together, the above data confirm our findings that Bcl-2 Thr56 phosphorylation is required for LRRK2 G2019S-induced excessive mitophagy. Importantly, Bcl-2 Thr56 phosphorylation might be implicated in LRRK2 G2019S-induced neurodegeneration. 
Discussion
In this study, we have confirmed that the LRRK2 G2019S mutation caused mitochondrial damage and exacerbated mitophagy. Importantly, we provide evidence that these aberrant events are, at least in part, mediated by Bcl-2 Thr56 phosphorylation caused by the G2019S mutation.
Bcl-2 can be regulated by post-translational modification by phosphorylation, dimerization, and proteolytic cleavage [38, 42, 43] . Bcl-2 is the target of a number of kinases, and multiple conformational changes are expected, depending on the number and location of the phosphorylation residues. Phosphorylation of Bcl-2 induced a strong inhibition of anti-apoptotic potential by some kinases, including Raf-1 kinase and MAPK [44, 45] . Moreover, Bcl-2 phosphorylation by JNK and p38 MAPK is associated with a decrease in the anti-apoptotic potential of Bcl-2 via loss of MMP, release of cytochrome c, and activation of caspases [45, 46] . Thus, Bcl-2 phosphorylation might alter the stability of this protein, signaling for mitochondrial impairment and cellular damage, although the detailed transduction pathway is not yet clear. In this study, we report for the first time that LRRK2 interacted with Bcl-2 directly and that the G2019S mutant specifically phosphorylated Bcl-2 at Thr56 residue. The importance of Bcl-2 Thr56 phosphorylation was further supported by the findings that a site-directed mutant, Bcl-2 T56A (non-phosphorylated), reversed the G2019S-induced mitochondrial depolarization and blocked mitochondrial mass loss. As another line of evidence, stable expression of either Bcl-2 wild-type (Bcl-2) or a mitochondrial targeting Bcl-2 (M-Bcl2) not only maintained the MMP but also corrected the G2019S-induced elevated autophagic flux and mitochondrial mass loss. Thus, we propose that Thr56 phosphorylation of Bcl-2 by LRRK2 G2019S might be a crucial step of mitochondrial disorder, which initiates the subsequent cellular damage in the context of PD relevant to G2019S. Several lines of evidence show that the dysfunctional mitochondria and disrupted autophagy are co-exhibited in patient fibroblasts carrying the LRRK2 G2019S mutant and primary neurons overexpressing LRRK2 G2019S [16, 41, 47, 48] . Moreover, transgenic mice expressing the LRRK2-G2019S mutation show mitochondrial alterations together with excessive mitophagy [18] . Thus, decreased membrane potential caused by Bcl-2 Thr56 phosphorylation in cells expressing the LRRK2 G2019S mutation, may cause mitochondrial damage and exacerbate mitophagy, which in turn leads to increased mitochondrial clearance. In this study, we found increased mitophagy in cells with LRRK2 G2019S, which was accompanied by mitochondrial depolarization, recruitment of p62 to the mitochondria, increased LC3II levels and lysosomal activity. Parkin recruitment to the depolarized mitochondria induced by the protonophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP) promotes ubiquitination of mitochondrial outer membrane proteins, and induces mitophagy [49] . The involvement of p62 in Parkin-related mitophagy is controversial [37, 50, 51] . Given that HeLa cells do not express Parkin, in our study, LRRK2 G2019S-induced mitochondrial mass loss might be independent of Parkinrelated mitophagy. Instead, p62 might play an active role in LRRK2 G2019S-induced mitochondrial degradation; downregulation of p62 corrected mitochondrial mass loss and lysosomal hyperactivity in the presence of LRRK2 G2019S. In addition, previous studies showed that mitochondrial biogenesis modulates mitochondrial mass in cardiac hypertrophy [52] and renal ischemia-reperfusion injury [53] . Thus, it remains to be determined as to whether LRRK2 G2019-induced loss of mitochondrial mass is due to lower activity of mitochondrial biogenesis.
In summary, in this study, we demonstrated that LRRK2 G2019S caused mitochondrial mass loss, at least in part, through phosphorylation of Bcl-2 at Thr56. Thus, our findings provide new insight into the mechanism by which LRRK2 G2019S causes mitochondrial disorder and cellular damage, revealing a potential therapeutic target to prevent G2019S-induced neurodegeneration.
